Advanced Ovarian Cancer Responds to Claudin-Targeted Drug in Preliminary Trial

(MedPage Today) -- SAN DIEGO -- Half of heavily pretreated patients with platinum-refractory ovarian cancer (PROC) responded to an investigational antibody-drug conjugate (ADC) targeting Claudin 6 (CLDN6), a small study from China showed. Overall...
Source
MedPage Today
Opens original article in a new tab



